29 June 2026
As the first three-year term of the Medicines Patent Pool’s (MPP) Community Advisory Panel (CAP) has come to a close for most CAP members, we would like to extend our sincere thanks to all members for their commitment, expertise and engagement since 2023.
Established to bring community perspectives into the heart of MPP’s work, the CAP brings together representatives from diverse regions and disease areas, including people with lived experience and strong links to their communities. Their role is central to ensuring that MPP’s approach to licensing and access is informed by real-world needs and grounded in the realities of those most affected by health inequities.
Over the past three years, CAP members have brought critical, on-the-ground perspectives into MPP’s work, helping to ensure that licensing priorities and access strategies are informed by the realities of those most affected. Through their engagement in consultations, events and ongoing dialogue, they have helped strengthen the relevance and responsiveness of MPP’s approach, while also supporting access efforts within their own countries and regions.
As Charles Gore, Executive Director of MPP, noted: “The CAP is an important reminder that our work is shaped by, and connected to, communities around the world. Their voices are not external to our work; they are part of how we operate.”
We are grateful to all CAP members for the time and insight they have contributed over the past three years. As many members continue into a new term, MPP is launching a call for application to bring additional voices into the panel, particularly from underrepresented regions and disease areas.
More on MPP’s Community Advisory Panel
Access the Call for Application
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.